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ABSTRACT: The full absolute conﬁguration assignment of phosphoeleganin (1), a
recently discovered marine-derived phosphorylated polyketide with protein tyrosine
phosphatase 1B inhibitory activity, was achieved. It was based on the synthesis of model
diasteroisomeric compounds of the C-8−C-12 segment portion of phosphoeleganin,
chiral derivatization methods, and application of the universal NMR database concept.
The problem of relative and absolute conﬁgurationelucidation of acyclic scaﬀolds is an important challenge
in natural products chemistry. Often, integrated approaches are
needed, which require rigorously acquired data obtained by a
combination of diﬀerent tools, including chemical manipulation
of the original molecule and organic synthesis.1,2 Databases of
spectroscopic information can be a great resource for
stereostructure determination, too. For example, Kishi and
co-workers, on the basis of their extensive experience with
polyketide chemistry and synthesis, developed an NMR
database of several motifs common to these molecules. This
data collection, known as the “universal NMR database”
(UDB), allowed simpliﬁed protocols to be used for the relative
and absolute conﬁguration assignment of unknown polyketides
without degradation and/or derivatization work.3−6
We have recently isolated phosphoeleganin (1), a new
phosphorylated polyketide with protein tyrosine phosphatase
1B (PTP1B) inhibitory activity, from the Mediterranean
ascidian Sidnyum elegans.7 By a combination of spectroscopic
analysis and microscale chemical degradation and/or derivati-
zation, we established the planar structure of 1, as well as its
conﬁguration except for the absolute conﬁgurations of the
carbinol centers C-11 and C-12. This provided two alternative
stereostructures for the natural metabolite, corresponding to
the 8S, 11S, 12R, 15S, 16R or 8S, 11R, 12S, 15S, 16R
conﬁgurations.
■ RESULTS AND DISCUSSION
Here, we report the unequivocal 8S, 11S, 12R, 15S, 16R
stereochemical assignment of phosphoeleganin, performed by a
combination of organic synthesis and chiral derivatization
methods directed to the application of the UDB concept.
Indeed, the logic used in this approach is that, given a complex
molecule composed of structural clusters of stereogenic centers
connected by a number of methylene bridges, we can assume
that (A) the structural properties of these clusters are inherent
to the speciﬁc stereochemical arrangement of the substituents
on the carbon backbone and (B) the structural properties of
these clusters are independent from the rest of molecule, when
they are suﬃciently separated from each other.6 In practice, the
stereogenic subunits need only to be separated by two or more
methylene groups so that they may be treated independently.
On this basis, we considered the C-8−C-12 stereocluster of
phosphoeleganin, in which the S absolute conﬁguration at C-8
and the anti relationship at C-11/C-12 had been previously
assigned.7 We decided to compare the 1H and 13C NMR
chemical shifts of this stereocluster with those of synthetic
compounds with known conﬁguration. We did not ﬁnd any
suitable molecule for comparison in the Kishi’s universal NMR
database; therefore, we decided to prepare the 8,9-anti
stereoisomers of tetradecane-5,8,9-triol to be used as model
compounds. For this purpose, the cis-4-decenal (2) was
converted to the (Z)-tetradec-8-en-5-ol (racemate) 3 by
coupling with n-BuLi. Then, 3 was treated with N-
methylmorpholine oxide (NMO) and 1% OsO4 to give a
mixture of the four 8,9-anti stereoisomers of tetradecane-5,8,9-
triol. Separation by reversed-phase HPLC of the reaction
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mixture aﬀorded two diastereoisomeric fractions (4 and 5) as
racemates. The chemical characterization of compounds 4 and
5 was performed through spectroscopic analyses (Experimental
Section). Both 4 and 5 were separately derivatized with three
equivalents of (R)-methoxyphenylacetic acid (R-MPA) to
aﬀord, in each case, a diastereoisomeric mixture of tris-(R)-
MPA esters, 4a/4b and 5a/5b, respectively (Scheme 1). The
four (R)-MPA derivatives were obtained as individual
compounds by HPLC separation on a silica gel column, and
their 1H NMR spectra were registered. According to the
approach proposed by Riguera’s group for the assignment of
the relative conﬁguration of acyclic sec/sec-1,n-diols by double
derivatization,8,9 we calculated the chemical shift diﬀerences
(Δδ) in the pairs 4a/4b and 5a/5b. It is to be noted that in our
case it was not necessary to prepare the two (R and S) tris-
chiral derivatizing agent esters since the (S)-MPA derivatives of
4a and 5a would be enantiomeric to the (R)-MPA derivatives
of 4b and 5b, respectively, and, consequently, their NMR
chemical shifts would be identical.10 Calculation of the Δδ
values in the 4a/4b pair (δH-4a − δH-4b or δH-4b − δH-4a)
led to negative (or positive) values for the C-1−C-5 segment
and positive (or negative) values for the C-8−C-14 segment
(Figure 1a); in contrast, all positive (or negative) Δδ (δH-5a −
δH-5b or δH-5b − δH-5a) values were obtained for the C-5−
C-8 segment in the 5a/5b couple (Figure 1b). Finally,
comparison of the sign distributions in both pairs with the
trends evidenced in every isomer of acyclic sec/sec-1,4-diols9
suggested a 5,8-anti relative conﬁguration in the 4a/4b couple
and a 5,8-syn relative conﬁguration in the 5a/5b pair (Figure 1).
Actually, as depicted in Figure 1, the patterns in the Δδ
values’ sign distribution were not perfectly homogeneous,
especially in the pair 4a/4b, where anomalies were detected for
the protons whose signals are diagnostic. Combined shielding/
deshielding eﬀects of the MPA units close enough to each other
possibly produce these anomalies and increase the degree of
uncertainty in the stereochemical assignment.11 Therefore, we
decided to substantiate the (5S*,8S*,9R*) and the
(5S*,8R*,9S*) relative conﬁguration assignments in com-
pounds 4a/4b and 5a/5b, respectively, by chemical means.
The enantiomerically pure tetradecane-5,8,9-triol 6 was
obtained from the base-catalyzed methanolysis of the tris-(R)-
MPA ester 4a. Then, we performed the stereoselective
synthesis of a tetrahydrofuran ring through a one-pot method
involving the formation of cyclic ortho esters generated in situ
via trimethyl orthoacetate12 (Scheme 2). The ionization of the
intermediate ortho ester 7 with the Lewis acid BF3 led to an
acetoxonium species, which, upon nucleophilic intramolecular
displacement with the hydroxy group at C-5, aﬀorded the
cyclized ether 8 in excellent yield (Scheme 2). Analogously,
compound 9, derived from the base-catalyzed methanolysis of
5a, was converted into the ether 11 (Scheme 2).
A trans and cis relationship across the tetrahydrofuran (THF)
rings in compounds 8 and 11, respectively, was then established
by ROESY experiments. Particularly, strong dipolar couplings
were observed between H-5 and H-8 in compound 11, whereas
we did not detect any ROE correlation between these two
protons for compound 8 (Figure 2).
These results, combined with the stereoselective outcome of
the cyclization reaction, where the conﬁguration at C-8 is
inverted, were in agreement with an anti−anti relative
conﬁguration in compound 7 and a syn−anti relative
conﬁguration in compound 10. Thus, the (5S*,8S*,9R*) and
the (5S*,8R*,9S*) relative conﬁgurations were deﬁnitely
assigned to the tetradecane-5,8,9-triols 6 and 9, respectively.
Finally, the NMR data of the tetradecane-5,8,9-triols 6 and 9
were compared to those of the C-8−C-12 portion of the natural
phosphoeleganin (1). This evaluation provided evidence that
proton and carbon NMR resonances of this portion match with
those of (5S*,8S*,9R*)-tetradecane-5,8,9-triol (6) [mean
average error (MAE): 13C = 0.16; 1H = 0.02 for compound 6
vs 13C = 0.64 and 1H = 0.07 for compound 9, Figure 3]. This
suggested an 8,11-anti relative conﬁguration in 1.
The absolute conﬁguration at C-8 in phosphoeleganin has
been previously established as S. Thus, the assignment of the
relative conﬁguration of the C-8−C-11 segment as anti required
an absolute conﬁguration at C-11 of S. Analogously, the C-11−
C-12 anti conﬁguration, previously established, too, required an
Scheme 1. Synthesis of the Four 8,9-anti Stereoisomers of 5,8,9-Tetradecanetriola,b
aReagents and conditions: (a) n-BuLi, anhydrous THF, −78 °C (10 min), rt (8 h); (b) NMO, 1% OsO4, acetone/H2O, 9:1, rt overnight; (c) HPLC
(Luna C18 10 μm, MeOH/H2O, 7:3); (d) EDC, DMAP, (R)-MPA, CH2Cl2, rt overnight.
bR = (R)-MPA.
Figure 1. (a) Δδ sign distribution patterns for the MPA esters of the
pairs 4a/4b and (b) 5a/5b.
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absolute conﬁguration at C-12 of R. Therefore, the absolute
conﬁguration of phosphoeleganin was completely determined
as 8S, 11S, 12R, 15S, 16R.
In summary, the design and synthesis of model diastereoiso-
meric compounds of the C-8−C-12 segment portion of
phosphoeleganin enabled the full absolute conﬁguration
assignment of the natural metabolite. Moreover, the whole of
our studies have great signiﬁcance for those who are working in
stereochemical assignments of complex ﬂexible acyclic scaﬀolds,
such as polyketides. First, in this context, the usefulness of
NMR databases clearly appeared. Particularly, in the logic of the
UDB concept, the possibility that a small motif present in a
larger natural product could be easily obtained by limited
synthetic eﬀort and used as a model compound represents an
eﬃcient and reliable simpliﬁed protocol in stereostructure
determination. When this procedure is performed for several
molecules within a pool of structurally analogous compounds,
representing a class of molecules, it is conceivable to assemble a
dedicated NMR database for this class, thus reducing the
synthetic eﬀorts. Finally, it is to be noted that, although
Riguera’s approach for the conﬁguration assignments of acyclic
1,n-diols has been rigorously validated,9,11 in our attempt to
determine the absolute conﬁguration of the synthetic
tetradecane-5,8,9-triols by analysis of their poly-MPA deriva-
tives, the obtained data appeared not completely reliable due to
the combined anisotropy eﬀects. In these cases, 1,2,n-triol
stereocontrolled cyclization strategies, such as the practical
cyclization to construct THF rings from 1,2,5-triols based on
the Lewis acid-mediated cyclization of cyclic ortho-esters, was
proved to be a valuable conclusive proof.
Scheme 2. Preparation and Stereoselective Cyclization of Tetradecane-5,8,9-triols 6 and 9a,b
aReagents and conditions: (a) NaOH, MeOH, rt, overnight; (b) MeC(OMe)3 (1.2 equiv), PPTS (0.1 equiv), CH2Cl2, 15 min, rt; (c) BF3·Et2O (0.1
equiv), 0 °C, H2O/acetone, 9:1.
bR = (R)-MPA.
Figure 2. Key ROE correlations for 8 and 11.
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■ EXPERIMENTAL SECTION
General Experimental Procedures. Optical rotations were
measured at 589 nm with a Jasco P-2000 polarimeter using a 10 cm
microcell. ECD spectra were recorded with a J-710 spectropolarimeter
(Jasco) with J-710 for Windows software (Jasco). 1H (700 MHz) and
13C (175 MHz) NMR spectra were recorded on a Agilent INOVA
spectrometer; chemical shifts were referenced to the residual solvent
signal (CD3OD: δH = 3.31, δC = 49.0; CDCl3: δH = 7.26, δC = 77.0).
Homonuclear 1H connectivities were determined by COSY experi-
ments. Two- and three-bond 1H−13C connectivities were determined
by gradient 2D HMBC experiments optimized for a 2,3J of 8 Hz.
HRMS (ESI positive mode) was performed with a Thermo LTQ
Orbitrap XL mass spectrometer. The spectra were recorded by
infusion into the ESI source using MeOH as solvent. HPLC separation
was achieved on a Knauer K-501 apparatus equipped with an Knauer
K-2301 RI detector.
Synthesis of (Z)-Tetradec-8-en-5-ol (3). (Z)-Tetradec-8-en-5-ol
was prepared from a solution of cis-4-decenal (424 mg, 2,75 mmol, 1.0
equiv) in anhydrous THF (20 mL) to which was added n-BuLi
dropwise (2.06 mL, 1.6 M in hexane, 3.30 mmol, 1.2 equiv). The
reaction mixture was stirred at −78 °C for 10 min and then for an
additional 8 h at room temperature (rt). The reaction was quenched
with saturated NH4Cl and extracted with EtOAc. The organic phase
was dried over anhydrous Na2SO4, and solvent removed with rotary
evaporation to yield the desired alcohol in 90% yield (524 mg). 1H
NMR (700 MHz, CDCl3, J in Hz) δ 0.84 (6H, m, H-1 and H-14),
1.20−1.51 (14H, overlapped, H-2/H4, H-9, H-11/H-13), 1.96 (2H,
m, H-5), 5.32 (2H, m, H-6 and H-7), 2.10, (1H, m, H-8a), 2.06 (1H,
m, H-8b), 3.54 (1H, m, H-10); 13C NMR (175 MHz, CDCl3) δ 14.1
(CH3, C-1 and C14), 22.5 (CH2), 22.7 (CH2), 22.4 (CH2), 27.1
(CH2), 27.7 (CH2), 29.3 (CH2), 31.4 (CH2), 37.0 (CH2), 37.1 (CH2),
71.5 (CH, C-5), 129.1 (CH), 130.5 (CH); ESIMS m/z 213.22 [M +
H]+.
Synthesis of 4 and 5. (Z)-Tetradec-8-en-5-ol (495 mg, 2.3 mmol,
1 equiv) was dissolved with acetone/H2O (9:1, 10 mL), and NMO
(410 mg, 3.5 mmol, 1.5 equiv) and OsO4 (1 mol %, 6 mg) were added.
The reaction mixture was stirred overnight at rt. The reaction was
quenched with saturated Na2SO3 solution and extracted with EtOAc
(3×). The organic layer was dried over anydrous Na2SO4, ﬁltered, and
concentrated in vacuo. Part of the organic layer was puriﬁed by
reversed-phase HPLC (Luna C18 10 μ MeOH/H2O, 7:3), providing
two diastereoisomeric fractions, 4 (55.1 mg, tR 12.6 min) and 5 (61.4
mg, tR 14.4 min), as enantiomeric mixtures. 4:
1H NMR (700 MHz,
CDCl3, J in Hz) δ 0.92 (3H, t, J = 7.6 Hz, H-1), 1.43 (1H, overlapped,
H-2a), 1.32 (1H, overlapped, H-2b), 1.32 (2H, overlapped, H-3), 1.46,
(1H, m, H-4a), 1.42 (1H, overlapped, H-4b), 3.53 (1H, m, H-5), 1.72
(1H, m, H-6a), 1.39 (1H, overlapped, H-6b), 1.80 (1H, m, H-7a), 1.39
(1H, overlapped, H-7b), 3.34 (1H, m, H-8), 3.36 (1H, m, H-9), 1.60
(1H, overlapped, H-10a), 1.36 (1H, overlapped, H-10b), 1.54 (1H, m,
H-11a), 1.33 (1H, overlapped, H-11b), 1.32 (2H, overlapped, H-12),
1.34 (2H, overlapped, H-13), 0.92 (3H, t, J = 7.6 Hz, H-14); 13C NMR
(CDCl3, signals assigned from HSQC data) δ 14.1 (CH3, C-1), 28.7
(CH2, C-2), 32.8 (CH2, C-3), 37.9 (CH2, C-4), 72.9 (CH, C-5), 34.6
(CH2, C-6), 29.6 (CH2, C-7), 76.3 (CH, C-8), 75.9 (CH, C-9), 33.4
(CH2, C-10), 26.4 (CH2, C-11), 32.8 (CH2, C-12), 23.7 (CH2, C-13),
14.1 (CH3, C-14); ESIMS m/z 247.22 [M + H]
+.
5: 1H NMR (700 MHz, CDCl3, J in Hz) δ 0.92 (H-1, t, J = 7.6 Hz
7.6, 3H,), 1.44 (1H, overlapped, H-2a), 1.33 (1H, overlapped, H-2b),
1.32 (2H, overlapped, H-3), 1.46 (1H, m, H-4a), 1.42 (1H,
overlapped, H-4b), 3.55 (1H, m, H-5), 1.60 (1H, overlapped, H-6a),
1.53 (1H, overlapped, H-6b), 1.70 (1H, overlapped, H-7a), 1.48 (1H,
overlapped, H-7b), 3.37 (1H, m, H-8), 3.38 (1H, m, H-9), 1.60 (1H,
overlapped, H-10a), 1.36 (1H, overlapped, H-10b), 1.54 (1H,
overlapped, H-11a), 1.33 (1H, overlapped, H-11b), 1.32 (2H,
overlapped, H-12), 1.34 (2H, overlapped, H-13), 0.92 (3H, t, J =
7.6 Hz 7.6, H-14); 13C NMR (CDCl3, signals assigned from HSQC
Figure 3. (a) 1H and 13C chemical shift values (CD3OD) of the similar stereoclusters in phosphoeleganin (1), 6, and 9; (b) their calculated ΔδH
(δH1 − δH6 or 9) and ΔδC (δC1 − δC6 or 9).
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data) δ 14.1 (CH3, C-1), 28.7 (CH2, C-2), 32.8 (CH2, C-3), 37.9
(CH2, C-4), 72.1 (CH, C-5), 34.3 (CH2, C-6), 29.3 (CH2, C-7), 75.6
(CH, C-8), 75.6 (CH2, C-9), 33.4 (CH2, C-10), 26.4 (CH2, C-11),
32.8 (CH2, C-12), 23.7 (CH2, C-13), 14.1 (CH3, C-14); ESIMS m/z
247.25 [M + H]+.
Compounds 4a,b and 5a,b. The esteriﬁcation reaction was
carried out on both fractions 4 (5.1 mg, 0.048 mmol) and 5 (18.1 mg,
0.074 mmol) each dissolved in dry CH2Cl2 (3 mL). To a solution of 4
was added ethylene dichloride (EDC) (37.4 mg, 0.195 mmol), 4-
dimethylaminopyridine (DMAP) (11.8 mg, 0.096 mmol), and (R)-
methoxyphenylacetic acid (6.32 mg, 0.195 mmol). Instead, to a
solution of 5 was added EDC (63.3 mg, 0.334 mmol), DMAP (18.1
mg, 0.148 mmol), and (R)-methoxyphenylacetic acid (54.8 mg, 0.334
mmol). Each mixture was stirred overnight under a N2 atmosphere at
rt. After solvent evaporation, HPLC puriﬁcation of the two mixtures
on a SiO2 column (Luna SiO2 3 μm), eluting with hexane/EtOAc,
85:15 (v/v), gave two diastereoisomeric triesters, 4a (2.1 mg, tR 3.74
min), 4b (2.3, tR 4.64 min), 5a (7.8 mg, tR 3.12 min), and 5b (8.0 mg,
tR 4.32 min).
Compound 4a: 1H NMR (700 MHz, CDCl3, J in Hz) δ 0.67 (3H,
t, J = 7.6 Hz, H-1), 0.98 (2H, overlapped, H-2), 0.61 (2H, m, H-3),
0.98 (1H, overlapped, H-4a), 0.94 (1H, overlapped, H-4b), 4.42 (1H,
m, H-5), 0.88 (1H, overlapped, H-6a), 0.56 (1H, m, H-6b), 1.14 (1H,
m, H-7a), 0.93 (1H, overlapped, H-7b), 4.66 (1H, m, H-8), 5.09 (1H,
m, H-9), 1.39 (1H, overlapped, H-10a), 1.36 (1H, overlapped, H-10b),
1.22 (2H, overlapped, H-11), 1.22 (2H, overlapped, H-12), 1.25 (2H,
overlapped, H-13), 0.86 (3H, t, J = 7.6 Hz, H-14); 13C NMR (CDCl3,
signals assigned from HSQC data) δ 13.5 (CH3, C-1), 22.1 (CH2, C-
2), 26.2 (CH2, C-3), 33.4 (CH2, C-4), 74.9 (CH, C-5), 29.1 (CH2, C-
6), 24.0 (CH2, C-7), 74.7 (CH, C-8), 74.1 (CH, C-9), 29.9 (CH2, C-
10), 24.9 (CH2, C-11), 31.1 (CH2, C-12), 22.3 (CH2, C-13), 13.7
(CH3, C-14); ESIMS m/z 713.36 [M + Na]
+.
Compound 4b: 1H NMR (700 MHz, CDCl3, J in Hz) δ 0.84 (3H,
t, J = 7.6 Hz, H-1), 1.25 (2H, overlapped, H-2), 1.16 (2H, overlapped,
H-3), 1.48 (1H, m, H-4a), 1.39 (1H, m, H-4b), 4.80 (1H, m, H-5),
1.31 (2H, overlapped, H-6), 1.02 (1H, m, H-7a), 0.80 (1H,
overlapped, H-7b), 4.88 (1H, m, H-8), 4.40 (1H, m, H-9), 0.84
(1H, overlapped, H-10a), 0.79 (1H, overlapped, H-10b), 0.52 (1H, m,
H-11a), 0.46 (1H, m, H-11b), 1.31 (2H, overlapped, H-12), 0.91 (2H,
m, H-13), 0.68 (3H, t, J = 7.6 Hz, H-14); 13C NMR (CDCl3, signals
assigned from HSQC data) δ 13.8 (CH3, C-1), 22.3 (CH2, C-2), 27.1
(CH2, C-3), 33.9 (CH2, C-4), 74.7 (CH, C-5), 30.4 (CH2, C-6), 25.5
(CH2, C-7), 74.4 (CH, C-8), 74.7 (CH, C-9), 26.9 (CH2, C-10), 23.9
(CH2, C-11), 30.3 (CH2, C-12), 22.1 (CH2, C-13), 13.5 (CH3, C-14);
ESIMS m/z 713.36 [M + Na]+.
Compound 5a: 1H NMR (700 MHz, CDCl3, J in Hz) δ 0.68 (3H,
t, J = 7.6 Hz, H-1), 1.05 (2H, m, H-2), 0.83 (2H, overlapped, H-3),
1.31 (1H, overlapped, H-4a), 1.29 (1H, overlapped, H-4b), 4.83 (1H,
m, H-5), 1.46 (1H, overlapped, H-6a), 1.42 (1H, overlapped, H-6b),
1.44 (1H, overlapped, H-7a), 1.37 (1H, overlapped, H-7b), 5.07 (1H,
m, H-8), 4.69 (1H, m, H-9), 0.99 (2H, overlapped, H-10), 0.59 (1H,
overlapped, H-11a), 0.54 (1H, overlapped, H-11b), 0.82 (1H,
overlapped, H-12a), 0.74 (1H, m, H-12b), 0.91 (2H, m, H-13), 0.67
(3H, t, J = 7.6 Hz, H-14); 13C NMR (CDCl3, signals assigned from
HSQC data) δ 13.7 (CH3, C-1), 22.1 (CH2, C-2), 26.7 (CH2, C-3),
33.4 (CH2, C-4), 74.2 (CH, C-5), 29.9 (CH2, C-6), 25.9 (CH2, C-7),
74.5 (CH, C-8), 74.8 (CH, C-9), 27.6 (CH2, C-10), 23.9 (CH2, C-11),
30.9 (CH2, C-12), 22.1 (CH2, C-13), 13.7 (CH3, C-14); ESIMS m/z
713.37 [M + Na]+.
Compound 5b: 1H NMR (700 MHz, CDCl3, J in Hz) δ 0.81 (3H,
t, J = 7.6 Hz, H-1), 1.16 (2H, overlapped, H-2), 0.93 (2H, overlapped,
H-3), 1.21 (1H, overlapped, H-4a), 0.99 (1H, overlapped, H-4b), 4.53
(1H, m, H-5), 0.74 (2H, overlapped, H-6), 0.89 (1H, overlapped, H-
7a), 0.77 (1H, overlapped, H-7b), 4.61 (1H, m, H-8), 5.00 (1H, m, H-
9), 1.22 (1H, overlapped, H-10a), 1.16 (1H, overlapped, H-10b), 1.16
(2H, overlapped, H-11), 1.22 (2H, overlapped, H-12), 1.24 (2H,
overlapped, H-13), 0.85 (3H, t, J = 7.6 Hz, H-14); 13C NMR (CDCl3,
signals assigned from HSQC data) δ 13.8 (CH3, C-1), 22.4 (CH2, C-
2), 27.1 (CH2, C-3), 33.4 (CH2, C-4), 73.9 (CH, C-5), 28.8 (CH2, C-
6), 22.6 (CH2, C-7), 74.2 (CH, C-8), 74.4 (CH, C-9), 29.6 (CH2, C-
10), 29.4 (CH2, C-11), 31.4 (CH2, C-12), 22.4 (CH2, C-13), 13.9
(CH3, C-14); ESIMS m/z 713.36 [M + Na]
+.
Compounds 6. Pure triol enantiomer 6 was obtained from 4a (2
mg, 0.003 mmol) by a hydrolysis reaction with NaOH (400 mg, 10
mmol) in MeOH (3 mL) and a few drops of H2O. The mixture was
stirred at rt overnight, then diluted with HCl (1% solution) and
washed with brine, and the triol was extracted with 20 mL of BuOH
(3×). The organic extract was dried over anhydrous Na2SO4 and then
concentrated in vacuo. Reversed-phase HPLC (Luna 5 μm C18),
eluting with MeOH/H2O, 7:3, allowed triol puriﬁcation. (2 mg, tR 12.6
min). [α]25D +3.7 (c 0.009, MeOH);
1H NMR (700 MHz, CDCl3, J in
Hz) δ 0.92 (3H, t, J = 7.6 Hz, H-1), 1.43 (1H, overlapped, H-2a), 1.32
(1H, overlapped, H-2b), 1.32 (2H, overlapped, H-3), 1.46 (1H, m, H-
4a), 1.42, (1H, overlapped, H-4b), 3.53 (1H, m, H-5), 1.72 (1H, m, H-
6a), 1.39 (1H, overlapped, H-6b), 1.80 (1H, m, H-7a), 1.39 (1H,
overlapped, H-7b), 3.34 (1H, m, H-8), 3.36 (1H, m, H-9), 1.60 (1H,
overlapped, H-10a), 1.36 (1H, overlapped, H-10b), 1.54 (1H, m, H-
11a), 1.33 (1H, overlapped, H-11b), 1.32 (2H, overlapped, H-12),
1.34 (2H, overlapped, H-13), 0.92 (3H, t, J = 7.6 Hz, H-14); 13C NMR
(CDCl3, signals assigned from HSQC data) δ 14.1 (CH3, C-1), 28.7
(CH2, C-2), 32.8 (CH2, C-3), 37.9 (CH2, C-4), 72.9 (CH, C-5), 34.6
(CH2, C-6), 29.6 (CH2, C-7), 76.3 (CH, C-8), 75.9 (CH, C-9), 33.4
(CH2, C-10), 26.4 (CH2, C-11), 32.8 (CH2, C-12), 23.7 (CH2, C-13),
14.1 (CH3, C-14); ESIMS m/z 247.22 [M + H]
+ HREIMS m/z
247.2266 (calcd for C14H31O3, 247.2268).
Compound 9. Pure triol enantiomer 9 (3.6 mg, tR 14.4 min) was
obtained by the same reaction and puriﬁcation process (reversed-phase
HPLC MeOH/H2O, 7:3) as for 6 reported above, using 4.8 mg (0.007
mmol) of 5a. [α]25D +1.5 (c 0.015, MeOH);
1H NMR (700 MHz,
CDCl3, J in Hz) δ 0.92 (H-1, t, J = 7.6 Hz 7.6, 3H), 1.44 (1H,
overlapped, H-2a), 1.33 (1H, overlapped, H-2b), 1.32 (2H, over-
lapped, H-3), 1.46 (1H, m, H-4a), 1.42, (1H, overlapped, H-4b), 3.55
(1H, m, H-5), 1.60 (1H, overlapped, H-6a), 1.53 (1H, overlapped, H-
6b), 1.70 (1H, overlapped, H-7a), 1.48 (1H, overlapped, H-7b), 3.37
(1H, m, H-8), 3.38 (1H, m, H-9), 1.60 (1H, overlapped, H-10a), 1.36
(1H, overlapped, H-10b), 1.54 (1H, overlapped, H-11a), 1.33 (1H,
overlapped, H-11b), 1.32 (2H, overlapped, H-12), 1.34 (2H,
overlapped, H-13), 0.92 (3H, t, J = 7.6 Hz 7.6, H-14); 13C NMR
(CDCl3, signals assigned from HSQC data) δ 14.1 (CH3, C-1), 28.7
(CH2, C-2), 32.8 (CH2, C-3), 37.9 (CH2, C-4), 72.1 (CH, C-5), 34.3
(CH2, C-6), 29.3 (CH2, C-7), 75.6 (CH, C-8), 75.6 (CH2, C-9), 33.4
(CH2, C-10), 26.4 (CH2, C-11), 32.8 (CH2, C-12), 23.7 (CH2, C-13),
14.1 (CH3, C-14); ESIMS m/z 247.25 [M + H]
+; HREIMS m/z
247.2267 (calcd for C14H31O3, 247.2268).
Cyclization of Enantiomerically Pure 6. Compound 6 (10.4 mg,
0.0422 mmol, 1.0 equiv) was dissolved in CH2Cl2 (5 mL), and
trimethyl orthoacetate (7 μL, 1.2 equiv) and pyridinium p-
toluenesulfonate (PPTS) (0.100 mg, 0.01 equiv) were added at rt.
After 15 min, BF3·Et2O (0.53 μL, 0.1 equiv) was added at 0 °C, and
when TLC showed the absence of the orthoester, the mixture was
quenched with H2O/acetone (9:1) and the solvent was removed in
vacuo. Cyclized product 8 was obtained quantitatively. NMR data: 1H
NMR (700 MHz, CDCl3, J in Hz) δ 0.87 (3H, t, J = 7.6 Hz, H-1), 1.30
(2H, overlapped, H-2), 1.31 (1H, overlapped, H-3a), 1.25 (1H, m, H-
3b), 1.56 (1H, m, H-4a), 1.38, (1H, overlapped, H-4b), 3.88 (1H, m,
H-5), 1.98 (1H, m, H-6a), 1.44 (1H, overlapped, H-6b), 1.96 (1H, m,
H-7a), 1.58 (1H, overlapped, H-7b), 3.98 (1H, m, H-8), 4.86 (1H, m,
H-9), 1.53 (2H, overlapped, H-10), 1.27 (2H, overlapped, H-11), 1.28
(2H, overlapped, H-12), 1.30 (2H, overlapped, H-13), 0.92 (3H, t, J =
7.6 Hz, H-14), 2.08 (3H, s, COOCH3);
13C NMR (CDCl3, signals
assigned from HSQC data) δ 14.1 (CH3, C-1), 22.8 (CH2, C-2), 28.4
(CH2, C-3), 35.5 (CH2, C-4), 79.6 (CH, C-5), 32.4 (CH2, C-6), 28.4
(CH2, C-7), 79.3 (CH, C-8), 75.7 (CH, C-9), 31.1 (CH2, C-10), 31.9
(CH2, C-11), 25.6 (CH2, C-12), 22.8 (CH2, C-13), 14.1 (CH3, C-14),
21.3 (CH3, COOCH3), 171.4 (C, COOCH3); ESIMS m/z 271.22 [M
+ H]+; HREIMS m/z 271.2270 (calcd for C16H31O3, 271.2273).
Cyclization of Enantiomerically Pure 9. Using 10.5 mg of 7
(0.0422 mmol, 1.0 equiv), compound 11 was obtained under the same
conditions as for 8 reported above. NMR data: 1H NMR (700 MHz,
CDCl3, J in Hz) δ 0.87 (3H, t, J = 7.6 Hz, H-1), 1.30 (2H, overlapped,
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H-2), 1.31 (1H, overlapped, H-3a), 1.25 (1H, m, H-3b), 1.56 (1H,
overlapped, H-4a), 1.40, (1H, overlapped, H-4b), 3.81 (1H, m, H-5),
1.92 (1H, overlapped, H-6a), 1.44 (1H, overlapped, H-6b), 1.89 (1H,
overlapped, H-7a), 1.62 (1H, overlapped, H-7b), 3.91 (1H, m, H-8),
4.87 (1H, m, H-9), 1.56 (2H, overlapped, H-10), 1.27 (2H,
overlapped, H-11), 1.28 (2H, overlapped, H-12), 1.29 (2H, over-
lapped, H-13), 0.87 (3H, t, J = 7.6 Hz, H-14), 2.09 (3H, s, COOCH3);
13C NMR (CDCl3, signals assigned from HSQC data) δ 14.1 (CH3, C-
1), 22.9 (CH2, C-2), 28.5 (CH2, C-3), 35.5 (CH2, C-4), 80.1 (CH, C-
5), 31.2 (CH2, C-6), 27.8 (CH2, C-7), 79.6 (CH, C-8), 75.9 (CH, C-
9), 31.2 (CH2, C-10), 31.9 (CH2, C-11), 25.2 (CH2, C-12), 22.6
(CH2, C-13), 14.1 (CH3, C-14), 21.3 (CH3, COOCH3), 171.4 (C,
COOCH3); ESIMS m/z 271.22 [M + H]
+; HREIMS m/z 271.2269
(calcd for C16H31O3, 271.2273).
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